AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) reported that sonesitatug vedotin reduced death risk by 42% versus investigator’s choice in second- and later-line advanced gastric cancers.
The Phase III CLARITY-Gastric01 planned interim analysis showed median overall survival of 10.6 versus 6.4 months in the overall population, a secondary endpoint. In third- and later-line treatment, a primary endpoint, death risk fell 53%, with median survival of 10.0 versus 5.0 months. Survival benefits were consistent across most predefined subgroups, including CLDN18.2 expression levels.
The other primary endpoint, independently reviewed progression-free survival—time without disease worsening or death—did not reach statistical significance: medians were 4.2 versus 3.8 months. Grade 3 or higher treatment-related adverse events occurred in 36.4% versus 44.8% of patients. No new safety signals were identified.
AstraZeneca (AZN) reported that TAGRISSO plus savolitinib reduced disease progression or death risk by 45% versus chemotherapy in Phase III SAFFRON.
The trial enrolled patients with EGFR-mutated non-small cell lung cancer, high MET overexpression or amplification, and progression on prior TAGRISSO. Median progression-free survival, the time without disease worsening or death, was 7.6 versus 5.4 months. Death risk fell 32%, with median overall survival of 17.8 versus 12.9 months. Both improvements were statistically significant.
Grade 3 or higher adverse events from all causes occurred in 64% versus 63%; median treatment exposure was 8.5 versus 3.5 months. A US application was submitted for the combination after progression on EGFR-targeted therapy in locally advanced or metastatic disease with MET overexpression or amplification. The combination is already approved in China for a MET-amplified population.
AstraZeneca (AZN) reported that IMFINZI plus Amgen’s tarlatamab-dlle reduced death risk by 58% versus IMFINZI alone in Phase III DeLLphi-305.
The planned interim analysis evaluated first-line maintenance treatment for extensive-stage small cell lung cancer after patients had not progressed on IMFINZI plus platinum chemotherapy and etoposide. Median overall survival was 21.1 months versus 12.7 months. The combination reduced the risk of progression or death by 66%, with median progression-free survival of 7.4 months versus 1.9 months. Both endpoints were statistically significant, with p<0.001. Confirmed tumor response rates were 26.4% versus 4.1%, and median response duration was 12.7 months versus 5.6 months. Grade 3 and 4 treatment-related adverse events occurred in 20.9% versus 10.8%; the combination caused no treatment-related fatalities.
AstraZeneca (AZN) reported that its IMFINZI combination reduced the risk of death by 42% in the Phase III VOLGA bladder cancer trial.
The planned interim analysis tested IMFINZI before and after surgery plus enfortumab vedotin before surgery in patients ineligible for or refusing cisplatin-based chemotherapy. The comparator was bladder removal with or without approved postoperative treatment. The combination reduced the risk of progression, recurrence, not undergoing surgery or death by 49%. Estimated two-year event-free survival was 64% versus 45%; overall survival was 78% versus 69%. Median event-free survival was not reached versus 12.1 months; median overall survival was not reached in either arm.
Grade 3–4 adverse events from any cause occurred in 64% versus 44%. No new safety signals were identified. The FDA granted the regimen Priority Review in September 2026.
AstraZeneca (AZN) has launched ZEGFROVY in the US for adults with previously treated lung cancer carrying EGFR exon 20 insertion mutations. Eligibility requires locally advanced or metastatic non-small cell lung cancer, mutations detected by an FDA-approved test, and progression on or after platinum-based chemotherapy.
The FDA granted accelerated approval based on WU-KONG1B, which showed a 46% confirmed response rate among 85 patients. Median response duration was 11.1 months among 39 responders; 72% had responses lasting at least six months. Continued approval may depend on confirmatory evidence of clinical benefit. Serious risks include lung inflammation, gastrointestinal reactions, severe rash, eye toxicity and fetal harm. Applications for first-line approval have also been submitted to US and Chinese regulators, both of which granted Breakthrough Therapy Designation in that setting.
AstraZeneca (AZN) and Amgen’s TEZSPIRE met both co-primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis. Both doses improved tissue remission and swallowing difficulties versus placebo at week 24, with benefits sustained through week 52.
Given every four weeks, the 210mg and 420mg doses achieved tissue remission in 64.8% and 68.9% of patients at week 24 versus 3.5% with placebo. Swallowing symptom scores fell 18.8 and 22.0 points, respectively, versus 14.7 points with placebo. At week 52, tissue remission rates were 67.8% and 63.3% versus 5.4%; total endoscopic remission—no visible disease features—reached 34.4% and 29.5% versus 4.1%.
The most frequent adverse events were upper respiratory infection, headache and diarrhea. Results were presented at United European Gastroenterology Week 2026.
AstraZeneca (AZN) will present overall survival data from four pivotal Phase III cancer trials at ESMO, October 23–27, 2026. More than 100 abstracts will feature its medicines and pipeline, including five pivotal Phase III trials.
CLARITY-Gastric01 showed a statistically significant overall survival benefit for sonesitatug vedotin versus investigator’s choice of therapy in second- or later-line advanced gastric or gastroesophageal junction cancers with CLDN18.2 expression ≥25%. Other Presidential Symposium presentations cover SAFFRON, testing TAGRISSO plus savolitinib after prior treatment in MET-driven, EGFR-mutated lung cancer; DeLLphi-305, testing IMFINZI plus tarlatamab as maintenance treatment in extensive-stage small cell lung cancer; and VOLGA, testing an IMFINZI-based combination in muscle-invasive bladder cancer. The China-based SANOVO trial tests TAGRISSO plus savolitinib in previously untreated lung cancer.
AstraZeneca (AZN) opened a new global research and development center in Kendall Square, Cambridge, Massachusetts, expanding its research presence in the state.
The opening accompanies an investment of more than $1 billion in Massachusetts, part of its broader $50 billion US investment. AstraZeneca expects the Massachusetts investment to expand its workforce in the state by over 50 percent in the coming years. Together with its genomic medicine site at 100 Binney Street, the new center will house nearly 2,000 researchers and scientists. The 570,000-square-foot facility will support work on oncology, cell therapy, chronic disease and rare disease medicines.
Summit Therapeutics (SMMT) closed AstraZeneca’s (AZN) $2.0 billion equity investment to support development of its investigational cancer therapy ivonescimab.
AstraZeneca purchased approximately 108,955 preferred shares, convertible into Summit common shares at a 1:1,000 ratio. The implied common share price of $18.36 represents a premium to the closing trading price on the investment’s announcement day. Summit plans to use the funds to accelerate development across solid tumors, including combinations with sonesitatug vedotin and Datroway, drugs that deliver chemotherapy through antibodies. The FDA accepted Summit’s ivonescimab marketing application for filing in January 2026, with a target decision date of November 14, 2026.
Daiichi Sankyo (4568) and AstraZeneca (AZN) entered a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate Datroway combined with ivonescimab.
The collaboration covers multiple tumor types, including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer, testing the combination as an initial treatment. Datroway is an antibody-drug conjugate, which links an antibody to a cancer-killing drug, jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Each company will supply its respective compound and contribute to trial costs. AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will retain development and commercial rights to its respective medicine. The agreement establishes planned combination studies; it does not report results from them.